Sorafenib (Sor)
Sorafenib is a drug approved for the treatment of primary kidney cancer (advanced renal cell carcinoma), advanced primary liver cancer (hepatocellular carcinoma), and radioactive iodine resistant advanced thyroid carcinoma. Sorafenib is a small molecular inhibitor of several tyrosine protein kinases (VEGFR and PDGFR) and Raf kinases (more avidly C-Raf than B-Raf). Sorafenib also inhibits some intracellular serine/threonine kinases (e.g. C-Raf, wild-type B-Raf and mutant B-Raf). Sorafenib (Nexavar) is an orally active multikinase inhibitor that is approved in the EU for the treatment of hepatocellular carcinoma. Monotherapy with sorafenib prolongs overall survival and delays the time to progression in patients with advanced hepatocellular carcinoma who are not candidates for potentially curative treatment or transarterial chemoembolization.

Organism species: Pan-species (General)

CATALOG NO. PRODUCT NAME APPLICATIONS
Proteins n/a Complete Antigen of Sorafenib (Sor) Antigenic Transformation Customized Service Offer
Antibodies n/a Monoclonal Antibody to Sorafenib (Sor) Monoclonal Antibody Customized Service Offer
n/a Polyclonal Antibody to Sorafenib (Sor) Polyclonal Antibody Customized Service Offer
Assay Kits n/a CLIA Kit for Sorafenib (Sor) CLIA Kit Customized Service Offer
n/a ELISA Kit for Sorafenib (Sor) ELISA Kit Customized Service Offer